$JBSS

John B. Sanfilippo & Son (NASDAQ:JBSS) Releases Earnings Results, Beats Estimates By $0.27 EPS

John B. Sanfilippo & Son (NASDAQ:JBSS) announced its quarterly earnings, reporting an EPS of $1.43, exceeding analyst estimates of $1.16 by $0.27. The company's revenue reached $281.78 million, surpassing the consensus of $260.83 million. Additionally, John B. Sanfilippo declared a special dividend of $1.50 per share payable on May 21st, with the stock currently holding a "Hold" rating from analysts and an average price target of $109.00.

Original reporting
MarketBeat · MarketBeat
Published Apr 29, 2026, 9:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
John B. Sanfilippo & Son (NASDAQ:JBSS) Releases Earnings Results, Beats Estimates By $0.27 EPS — source image
Decision brief

The 30-second read

$JBSSBullishMed
01

Why it matters

The positive earnings and dividend are likely to boost investor confidence and stock price in the near term.

02

Market read

The earnings report and dividend announcement are significant for investors holding or considering JBSS stock.

03

What to watch

Potential macroeconomic headwinds or sector rotation could offset company-specific gains.

Timing: Immediate, as earnings are recent and dividend is upcoming.

Background

John B. Sanfilippo & Son reported quarterly earnings exceeding estimates and declared a special dividend, signaling strong financial performance.

Company-level read

Ticker impact

$JBSSBullishHigh confidence
Context

The earnings beat and dividend announcement are significant company-specific events that can influence stock price.

Expected impact

Moderate upward movement in the short term, potential for increased investor interest.

Evidence & confidence

Earnings beats and dividend announcements are typically viewed positively, likely leading to a price increase, especially given the company's solid revenue growth.

Market effects

Positive sentiment for the consumer staples sector, as JBSS operates within this industry.

Limited regional impact, primarily affecting investors in the company's primary markets.

Minimal global relevance, as the company is primarily US-based.

Counterpoint

The earnings beat may already be priced in; a correction could occur if future guidance is weak.

Key entities

  • John B. Sanfilippo & Son

    A manufacturer and distributor of snack foods.

Related articles

$JBSSMed

JBSS Q4 2026 Earnings Call Transcript

JBSS reported Q4 2026 net sales up 4.2% to $280.4M, but net income fell to $8.4M from $13.5M YoY. Challenges included higher costs and manufacturing inefficiencies. Priorities for 2027 include restoring snack volume, expanding the Thar portfolio, and managing cost volatility. The company expects $300M in potential new growth.

$JBSSMed

SANFILIPPO JOHN B & SON INC (JBSS): Results of Operations and Financial Condition

SANFILIPPO JOHN B & SON INC (JBSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 John B. Sanfilippo & Son, Inc. Reports Fiscal 2026 Fourth Quarter and Full Year Results Fourth Quarter Net Sales Increased 4.2%; Sales Volume Increased 1.4% Elgin, IL, August 19, 2026 -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced fi

$NXEMed

Is BHP Group (BHP) the Missing Piece in NexGen Energy (NXE)’s $1 Billion Financing Plan?

NexGen Energy (NXE) is in talks with BHP Group (BHP) for a potential equity stake and financing for its Rook I uranium project. NexGen aims to raise $1 billion over nine months. BHP reported strong financials, with $33 billion in EBITDA and $9.8 billion in free cash flow. NexGen has no revenue but holds $970.25 million in cash. Investors should watch for a formal partnership between the two.

$AZNMed

13 clinical candidates revealed in Chicago

At the American Chemical Society Fall 2026 meeting, 13 new drug candidates were unveiled by various companies, targeting diseases like cancer, lupus, and acne. Presenters included Quanta Therapeutics, AstraZeneca, Novartis, and Pfizer, among others, discussing their drug discovery strategies and clinical trials.